Floatz logo

TRASTUZUMAB

Pulmonary Carcinoid Tumor

National Cancer Institute (NCI)monoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Pulmonary Carcinoid Tumor cohort.

Asset / SponsorPhaseRating
Temsirolimus
National Cancer Institute (NCI)
Phase 2BB
Regorafenib
University of Southern California
Phase 2B
gw786034
National Cancer Institute (NCI)
Phase 2B
Romidepsin
National Cancer Institute (NCI)
Phase 2CCC
DOTATOC
British Columbia Cancer Agency
Phase 2CCC

View all 16 →

Same molecule, other indications

TRASTUZUMAB is also rated in:

breast carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
inflammatory breast carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
HER2/Neu PositiveDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →